Can postendoscopic retrograde cholangiopancreatography pancreatitis be prevented by a pharmacological approach?
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Acute pancreatitis remains the most frequent complication of endoscopic retrograde cholangiopancreatography (ERCP), with reported incidence rates that have changed little over several decades. Patient- and procedure-related risk factors for post-ERCP pancreatitis (PEP) are well-defined. Effective measures to prevent PEP have been identified, including improvements in cannulation techniques and pancreatic stenting, as well as pharmacological intervention. Pharmacotherapy has been widely studied in the prevention of PEP, but the effect in averting PEP has been inconclusive. Although pharmacological prophylaxis is appealing, attempts to find an ideal drug are incomplete. Most available data on the efficacy of pharmacological agents for PEP prophylaxis have been obtained from patients at average risk for PEP. However, recently, a randomized prospective controlled trial of rectal nonsteroidal anti-inflammatory drugs (NSAIDs) to prevent PEP in high-risk patients was published. The results revealed that rectal indomethacin reduced the incidence of PEP significantly. Thus, rectal administration of diclofenac or indomethacin immediately before or after ERCP is used routinely to prevent PEP. However, additional studies with NSAIDs using large numbers of subjects are necessary to confirm the prophylactic effect of these drugs and to establish whether they act synergistically with other prophylactic interventions, including pancreatic stenting.
Abstract
Acute pancreatitis remains the most frequent complication of endoscopic retrograde cholangiopancreatography (ERCP), with reported incidence rates that have changed little over several decades. Patient- and procedure-related risk factors for post-ERCP pancreatitis (PEP) are well-defined. Effective measures to prevent PEP have been identified, including improvements in cannulation techniques and pancreatic stenting, as well as pharmacological intervention. Pharmacotherapy has been widely studied in the prevention of PEP, but the effect in averting PEP has been inconclusive. Although pharmacological prophylaxis is appealing, attempts to find an ideal drug are incomplete. Most available data on the efficacy of pharmacological agents for PEP prophylaxis have been obtained from patients at average risk for PEP. However, recently, a randomized prospective controlled trial of rectal nonsteroidal anti-inflammatory drugs (NSAIDs) to prevent PEP in high-risk patients was published. The results revealed that rectal indomethacin reduced the incidence of PEP significantly. Thus, rectal administration of diclofenac or indomethacin immediately before or after ERCP is used routinely to prevent PEP. However, additional studies with NSAIDs using large numbers of subjects are necessary to confirm the prophylactic effect of these drugs and to establish whether they act synergistically with other prophylactic interventions, including pancreatic stenting.
참고문헌 (50)
- Freeman ML, "Complications of endoscopic biliary sphincterotomy", N Engl J Med, 335, pp.909~918 (1996)
- Masci E, "Risk factors for pancreatitis following endoscopic retrograde cholangiopancreatography: a meta-analysis", Endoscopy, 35, pp.830~834 (2003)
- Cheon YK, "Frequency and severity of post-ERCP pancreatitis correlated with extent of pancreatic ductal opacification", Gastrointest Endosc, 65, pp.385~393 (2007)
- Chen YK, "Endoscopic sphincterotomy-induced pancreatitis: increased risk associated with nondilated bile ducts and sphincter of Oddi dysfunction", Am J Gastroenterol, 89, pp.327~333 (1994)
- Freeman ML, "Prevention of post-ERCP pancreatitis: a comprehensive review", Gastrointest Endosc, 59, pp.845~864 (2004)
- Elmunzer BJ, "randomized trial of rectal indomethacin to prevent post- ERCP pancreatitis", N Engl J Med, 366, pp.1414~1422 (2012)
- Cotton PB, "Endoscopic sphincterotomy complications and their management: an attempt at consensus", Gastrointest Endosc, 37, pp.383~393 (1991)
- Murray WR., "Reducing the incidence and severity of post ERCP pancreatitis", Scand J Surg, 94, pp.112~116 (2005)
- Dumonceau JM, "European Society of Gastrointestinal Endoscopy (ESGE) Guideline: prophylaxis of post-ERCP pancreatitis", Endoscopy, 42, pp.503~515 (2010)
- Nishijima MK, "Application of HPLC measurement of plasma concentration of gabexate mesilate", Thromb Res, 31, pp.279~284 (1983)
- Cavallini G, "Gabexate for the prevention of pancreatic damage related to endoscopic retrograde cholangiopancreatography: gabexate in digestive endoscopy: Italian Group", N Engl J Med, 335, pp.919~923 (1996)
- Andriulli A, "Pharmacologic treatment can prevent pancreatic injury after ERCP: a meta-analysis", Gastrointest Endosc, 51, pp.1~7 (2000)
- Andriulli A, "Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial", Gastrointest Endosc, 56, pp.488~495 (2002)
- Fujishiro H, "Ulinastatin shows preventive effect on post-endoscopic retrograde cholangiopancreatography pancreatitis in a multicenter prospective randomized study", J Gastroenterol Hepatol, 21, pp.1065~1069 (2006)
- Tsujino T, "Ulinastatin for pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized, controlled trial", Clin Gastroenterol Hepatol, 3, pp.376~383 (2005)
- Ueki T, "Comparison between ulinastatin and gabexate mesylate for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: a prospective, randomized trial", J Gastroenterol, 42, pp.161~167 (2007)
- Yoo JW, "Preventive effects of ulinastatin on post-endoscopic retrograde cholangiopancreatography pancreatitis in high-risk patients: a prospective, randomized, placebo-controlled trial", Pancreas, 37, pp.366~370 (2008)
- Abdel Aziz AM, "Pancreatitis after endoscopic retrograde cholangio-pancreatography", World J Gastroenterol, 13, pp.2655~2668 (2007)
- Andriulli A, "Antisecretory vs. antiproteasic drugs in the prevention of post- ERCP pancreatitis: the evidence-based medicine derived from a meta-analysis study", JOP, 4, pp.41~48 (2003)
- Vila JJ, "Utility of bolus somatostatin administration in preventing pancreatitis after endoscopic retrograde cholangiopancreatography: a controlled, nonrandomized study", Gastroenterol Hepatol, 29, pp.231~236 (2006)
- Sternlieb JM, "A multicenter, randomized, controlled trial to evaluate the effect of prophylactic octreotide on ERCP-induced pancreatitis", Am J Gastroenterol, 87, pp.1561~1566 (1992)
- Binmoeller KF, "Effect of somatostatin analog octreotide on human sphincter of Oddi", Dig Dis Sci, 37, pp.773~777 (1992)
- Arcidiacono R, "The use of a long-acting somatostatin analogue (octreotide) for prophylaxis of acute pancreatitis after endoscopic sphincterotomy", Endoscopy, 26, pp.715~718 (1994)
- Tulassay Z, "Octreotide in the prevention of pancreatic injury associated with endoscopic cholangiopancreatography", Aliment Pharmacol Ther, 12, pp.1109~1112 (1998)
- Staritz M, "Effect of glyceryl trinitrate on the sphincter of Oddi motility and baseline pressure", Gut, 26, pp.194~197 (1985)
- Bang UC, "Metaanalysis: nitroglycerin for prevention of post-ERCP pancreatitis", Aliment Pharmacol Ther, 29, pp.1078~1085 (2009)
- Shao LM, "Nitroglycerin in the prevention of post-ERCP pancreatitis: a meta-analysis", Dig Dis Sci, 55, pp.1~7 (2010)
- Goldstein I, "Oral sildenafil in the treatment of erectile dysfunction: Sildenafil Study Group", N Engl J Med, 338, pp.1397~1404 (1998)
- Galie N, "Sildenafil citrate therapy for pulmonary arterial hypertension", N Engl J Med, 353, pp.2148~2157 (2005)
- Fries R, "Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy", Circulation, 112, pp.2980~2985 (2005)
- Eherer AJ, "Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders", Gut, 50, pp.758~764 (2002)
- Cheon YK, "Effects of vardenafil, a phosphodiesterase type-5 inhibitor, on sphincter of Oddi motility in patients with suspected biliary sphincter of Oddi dysfunction", Gastrointest Endosc, 69, pp.1111~1116 (2009)
- Oh HC, "Use of udenafil is not associated with a reduction in post-ERCP pancreatitis: results of a randomized, placebo-controlled, multicenter trial", Gastrointest Endosc, 74, pp.556~562 (2011)
- Prat F, "Nifedipine for prevention of post-ERCP pancreatitis: a prospective, double-blind randomized study", Gastrointest Endosc, 56, pp.202~208 (2002)
- Sand J, "Prospective randomized trial of the effect of nifedipine on pancreatic irritation after endoscopic retrograde cholangiopancreatography", Digestion, 54, pp.105~111 (1993)
- Makela A, "Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro", Scand J Clin Lab Invest, 57, pp.401~407 (1997)
- Niederau C, "Current conservative treatment of acute pancreatitis: evidence from animal and human studies", Hepatogastroenterology, 40, pp.538~549 (1993)
- Murray B, "Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography", Gastroenterology, 124, pp.1786~1791 (2003)
- Cheon YK, "Efficacy of diclofenac in the prevention of post-ERCP pancreatitis in predominantly high-risk patients: a randomized double-blind prospective trial", Gastrointest Endosc, 66, pp.1126~1132 (2007)
- van Hoogdalem EJ, "Pharmacokinetics of rectal drug administration, part II: clinical applications of peripherally acting drugs, and conclusions", Clin Pharmacokinet, 21, pp.110~128 (1991)
- van der Marel CD, "Diclofenac and metabolite pharmacokinetics in children", Paediatr Anaesth, 14, pp.443~451 (2004)
- Deviere J, "Interleukin 10 reduces the incidence of pancreatitis after therapeutic endoscopic retrograde cholangiopancreatography", Gastroenterology, 120, pp.498~505 (2001)
- Morrow JB, "Sedation for colonoscopy using a single bolus is safe, effective, and efficient: a prospective, randomized, double-blind trial", Am J Gastroenterol, 95, pp.2242~2247 (2000)
- Sherman S, "Efficacy of recombinant human interleukin-10 in prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis in subjects with increased risk", Pancreas, 38, pp.267~274 (2009)
- Budzynska A, "A prospective, randomized, placebocontrolled trial of prednisone and allopurinol in the prevention of ERCP-induced pancreatitis", Endoscopy, 33, pp.766~772 (2001)
- De Palma GD, "Use of corticosteriods in the prevention of post-ERCP pancreatitis: results of a controlled prospective study", Am J Gastroenterol, 94, pp.982~985 (1999)
- Sherman S, "Does prophylactic administration of corticosteroid reduce the risk and severity of post-ERCP pancreatitis: a randomized, prospective, multicenter study", Gastrointest Endosc, 58, pp.23~29 (2003)
- Toulon P, "Involvement of heparin cofactor II in chymotrypsin neutralization and in the pancreatic proteinase-antiproteinase interaction during acute pancreatitis in man", Eur J Clin Invest, 21, pp.303~309 (1991)
- Barkay O, "Low-dose heparin for the prevention of post-ERCP pancreatitis: a randomized placebo-controlled trial", Surg Endosc, 22, pp.1971~1976 (2008)
- Rabenstein T, "Low-molecular- weight heparin does not prevent acute post-ERCP pancreatitis", Gastrointest Endosc, 59, pp.606~613 (2004)